Organic Active Ingredients TRIZ Cases

A semihydrate Utidelone crystal form improves stability and bioavailability under heat and humidity while remaining suitable for industrial drug production.

Specific C17 fluorination and steroid substitutions improve NMDA modulation while limiting glutamate-driven neurotoxicity in CNS treatment.

A chitosan-collagen ointment base stabilizes Mupirocin while improving skin adherence, bacterial control, and wound healing speed.

Modified recombinant host cells use enzymatic and chemoenzymatic pathways to produce cannabinoid analogs more efficiently and sustainably.

Clay-mineral matrices and compression bias enable intra-ruminal delivery with linear release over extended periods and lower dosing frequency.

A gut-cleavable codrug releases a JAK inhibitor and berberine analog in the intestine to treat GI inflammation while limiting systemic adverse effects.

Coagglomerated crystalline mannitol and granular starch improve powder flow and tablet hardness, enabling capsule filling with less lubricant.

Targeting miR-21 inhibitors to lung macrophages improves uptake at lower doses, helping treat pulmonary fibrosis with fewer side effects.

Modulating SF-1 with pyrazolopyrimidinone compounds expands treatment options for cancer, endocrine disorders, and endometriosis.

Early-morning lipid mediator profiling uses n-3 DPA-derived resolvins to assess cardiovascular risk and curb platelet-leukocyte activation.

Ionizable cationic lipid particles co-encapsulate Cas9 mRNA and sgRNA to improve delivery of large genome-editing cargo into cells.

Specific indolyl oxazole, oxadiazole, and furan compounds boost boar sperm motility after storage, improving artificial insemination fertility.

Selective HPK1 inhibitor compounds target the kinase ATP-binding site to modulate immune signaling while limiting off-target MAP4K effects.

Substituted indole compounds inhibit complement factor B to sustain alternative pathway blockade and reduce proteinuria and renal injury.

A 5-amino phthalazinedione sodium salt addresses rare chronic pulmonary inflammation with anti-inflammatory efficacy and minimal adverse reactions.

Layered nanoparticles use HA targeting, siRNA silencing of Bcl-2 family proteins, and apoptotic peptides to kill RHAMM-positive tumors.

Novel azetidin-3-ylmethanol CCR6 modulators improve receptor targeting to reduce inflammation and inhibit tumor growth.

Purified cannabinoid receptor ligands replace smoked cannabis to improve dosing control, bioavailability, and avoid harmful smoke toxins.

A density-enhanced methotrexate formulation sinks through silicone oil in under 10 minutes to reach the retina and help prevent PVR after detachment repair.

A lyophilized DON prodrug with mannitol, cellulose, poloxamer, lecithin, and histidine enables subcutaneous dosing while reducing intestinal toxicity.

A buffered topical composition keeps skin pH at 4.5-5.5 for hours, supporting barrier function and easing eczema without irritation.

A nomegestrol acetate and estradiol oral contraceptive maintains contraception while lowering venous thromboembolism risk versus other CHCs.

Small-molecule fused pyrimidines activate KCC2 to restore GABA inhibition and reduce neuronal hyperexcitability in neurological disorders.

Early cabotegravir and rilpivirine dosing suppresses HIV, shrinks the latent reservoir, and delays viral rebound after treatment stops.

Solid plasticizers and pharmaceutical-grade oil keep lorazepam films stable while preserving rapid oral disintegration and shelf-life performance.

Engineered CAAR immune cells selectively remove autoantibody-producing B cells in CNS autoimmune disease while avoiding broad immunosuppression.

Scaffold tuning of hydroxypiperidine PRMT5 inhibitors improves selectivity, suppresses tumor growth, and boosts fetal globin expression.

Dual α2δ-1 and σ1 receptor ligands aim to improve chronic pain relief while reducing polypharmacy, side effects, and drug interactions.

Controlled niraparib particles with high surface area and 1-6 micron size improve dissolution, absorption, and oral formulation stability.

A sulfonate gradient in irinotecan liposomes improves encapsulation stability and sustained release while helping reduce toxicity.

High-organic solvent treatment loads antimicrobial agents evenly into CMC wound dressing fibres without gelling, preserving softness and release.

Hydrophilic iodinated polymer pendant groups improve radiopacity while preserving handling, drug loading, and predictable embolisation.

Multi-receptor heteroalicyclic compounds improve antipsychotic selectivity while reducing extrapyramidal and cognitive side effects.

Squalene-rich oils stabilize chlorophyll extract against heat, light, oxygen, and pH stress for long-term storage and direct food use.

Nitrogen-branched cationic lipids improve nucleic acid loading, serum stability, endosomal release, and transfection with lower cytotoxicity.

Bivalent indane compounds target PD-L1 and PD-1 interactions to improve oral drug stability, bioavailability, and response durability.

Novel thailanstatin A analog linkers enable targeted ADC payload release, improving anti-cancer efficacy while limiting systemic toxicity.

Selective Axl and Mer inhibitor compounds address kinase-driven tumor growth while reducing off-target effects through structure-based optimization.

Hydroxyl-group modification makes allopregnanolone water-soluble for oral dosing, improving bioavailability, stability, and sustained exposure.

Cell-permeable PARG inhibitors improve selectivity and DNA repair disruption to sensitize cancer cells with replication stress.

Selective Pd- and Cu-catalyzed C-H amination and oxidation produce pyridin-4(1H)-one KDM inhibitors with fewer steps and less waste.

Substituted heteroaryl compounds inhibit TLR9 while improving TLR7/8 selectivity, stability, and bioavailability for fibrotic disease therapy.

Covalent linker and antibody conjugates improve STING modulator selectivity, solubility, and circulation while reducing off-target toxicity.

ASBT inhibitor dosing with maralixibat improves growth and pruritus in pediatric cholestatic liver disease while increasing fecal bile acid excretion.

Solubilized estradiol and micronized progesterone improve oral bioavailability, lower dose needs, and reduce side effects from variable absorption.

Small-molecule PRMT5 inhibitors are tuned for selectivity, potency, and oral bioavailability to suppress tumors and raise fetal globin expression.

A rigid yet elastic gel dilator eases insertion, mechanically expands the vaginal canal, and releases therapeutic agents for narrowing, atrophy, and dryness.

Methacrylic acid copolymer or HPMC solid formulations improve dengue inhibitor stability while easing reconstitution and delivery.

Targeted IL-6R antibodies block inflammatory signaling in uveitis and macular edema, reducing edema while limiting corticosteroid side effects.

Small RNAs target IL-1beta, IL-6, and TNF-alpha to suppress inflammatory signaling, improve cell viability, and support treatment of related diseases.

Targeting brain glucose metabolism with glucokinase activators may slow cognitive decline and neurodegeneration linked to Type 2 diabetes.

Stepwise fluorination and stabilized intermediates improve porphyrin selectivity while reducing harsh conditions and byproduct formation.

A steroid-activated tBID fusion triggers rapid apoptosis in engineered cells, limiting off-target toxicity in adoptive cell therapy.

A thermo-responsive hydrogel with biodegradable microspheres extends anti-VEGF release, reducing repeat eye injections and related complications.

Targeting soluble guanylate cyclase early helps treat systemic sclerosis vasculopathy, reducing fibrosis and organ damage progression.

PEG conjugation improves indole alkaloid water solubility and metabolic stability for diabetic neuropathy, diabetic foot, and pulmonary fibrosis.

Targeted C9ORF72 inhibitors lower mRNA and protein expression to slow ALS and FTD progression linked to repeat expansions.

Reduced bupropion and dextromethorphan doses lower dextromethorphan exposure in CYP2D6 poor metabolizers while preserving antidepressant effect.

S-substituted nucleoside analogues target the parasite purine salvage pathway to improve anti-trypanosomal activity while reducing toxicity.

Repurposing vemurafenib enables broad enteroviral inhibition, lowering viral loads while preserving host cell viability.

A synthetic self-assembling peptide hydrogel seals tissue leakage and maintains hemostasis without animal-derived infection risk.

Selective Formula I plasma kallikrein inhibitors expand treatment options for hereditary angioedema and retinal vascular disorders.

CoQ10 given before or alongside chemotherapy helps limit organ toxicity and immune suppression while preserving tumor control and survival.

A pH-gradient liposomal weak acid formulation flattens plasma peaks, extends effect to 6 hours, and cuts PH dosing frequency.

Modified camptothecin linker-payload ADCs improve solid tumor targeting, overcome resistance, and reduce off-target toxicity.

Specific MAT2A inhibitor crystal forms use controlled polymorphism to maintain purity, chemical stability, and manufacturability for drug production.

Targeting abnormal PKCγ activity with flavonoid inhibitors helps relieve stress-, trauma-, and depression-related memory disorders with fewer side effects.

A mucoadhesive eye-drop composition uses hyaluronic acid, PEG, and verbascoside to resist tear washout, reduce friction, and support corneal healing.

A self-emulsifying docetaxel injection replaces Tween-80 to reduce allergic reactions while improving emulsion stability and preparation simplicity.

Gas-phase suspension boosts extraction efficiency while cutting time-at-temperature to preserve thermolabile natural products.

Site-specific antibody conjugation with transglutaminase and 1,3-cycloaddition improves tumor targeting while reducing normal-cell toxicity.

Radiolabeled cromolyn derivatives localize to mast cells and plaques, enabling earlier PET imaging and more targeted therapy for atherosclerosis and Alzheimer's.

Novel M3 muscarinic antagonists use a tunable Formula I scaffold to improve topical treatment options for hyperhidrosis and related disorders.

Humanized MUC1 and mutant K-ras antibody conjugates improve tumor detection and treatment while limiting binding to healthy tissue.

A multilayer biodegradable implant releases chemotherapy toward pancreatic tumor tissue while blocking off-target leakage and avoiding removal surgery.

DOPG nanovesicles bind soluble pHsp70 to disrupt TLR-linked M2 macrophage polarization and reduce tumor immunosuppression.

Combining a KRAS inhibitor with an IL-36γ oncolytic virus boosts tumor immunogenicity and adaptive immune response against KRAS-mutant cancers.

A substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazine scaffold improves BTK selectivity to treat autoimmune disease and cancer with fewer side effects.

Hydrophobic N6-modified mRNA cap analogs enable chromatographic separation of uncapped transcripts and improve protein expression in cells.

Free heme scavenging with hemopexin helps prevent halogen gas-induced lung injury by reducing ER stress and preserving lung function.

Sulfur and amide tropolone inhibitors block nucleotidyl transferases to suppress resistant viral and fungal replication with improved bioavailability.

Agitated blood incubation boosts IL-1Ra, exosomes, and anti-inflammatory mediator ratios while shortening production of autologous pharmaceutical compositions.

Targeting Hedgehog-driven myofibroblasts with taladegib reduces lung scarring and improves lung capacity in progressive pulmonary fibrosis.

Matched carrier particles, glidant, and protective packaging keep oral C21 powder stable against water and light while preserving dose uniformity.

Alginate matrices with ammonium citrate stabilize nicotine in high-water oral or nasal compositions while maintaining controlled release and storage stability.

Rapid controlled precipitation forms core-shell nanoparticles that protect soluble biologics, improve encapsulation, and extend release.

A crystal form Q4 improves stability and ALK mutant inhibition, helping extend drug effectiveness against resistance in NSCLC.

Targeting USP16 helps slow osteoarthritis progression by reducing senescence, inflammation, pain, and cartilage matrix degradation.

Sequence-specific aptamers bind Spike RBD and RdRp to block coronavirus infection and replication while also providing anticoagulatory effects.

By adding an ER export signal to chimeric rhodopsin, this case improves expression efficiency, visual restoration, and object recognition.

Merestinib plus LY2584702 targets S6K1 and TAM kinases to kill PTEN-deficient glioblastoma cells while avoiding broad brain damage.

Specific phosphate opicapone prodrugs raise solubility 100-fold while preserving stability and enabling safer in vivo conversion.

Opposing score markings and tuned rheology let a soft veterinary chew split into accurate doses with under 0.5% mass loss and lower contamination risk.

Blocking A2A and A1 adenosine receptors helps restore antitumor immunity and extend checkpoint therapy to more patients.

A pyrazolopyridine-indole GLP-1 agonist improves oral bioavailability and metabolic stability for non-invasive Type 2 diabetes and obesity treatment.

A gas-forming self-setting adhesive creates a porous bone scaffold that improves implant adhesion, osseointegration, and surgical handling.

Cyclic urea thiazolyl compounds inhibit the HSV helicase-primase complex to improve outbreak prevention with better potency and safety.

GalNAc-linked siRNA delivery chains improve liver uptake and nuclease stability for sustained HBV gene silencing with reduced toxicity.

Mutant SMEZ-2 carriers boost MHC class II antigen presentation to bypass T cell tolerance and raise anti-cancer immunoglobulin responses.

A low-dose flumazenil and naltrexone combination improves depression, anxiety, and PTSD symptoms while reducing side effects and regimen complexity.

A selective MC4R agonist composition suppresses appetite and supports weight loss while avoiding broad melanocortin side effects.

By pairing avelumab with axitinib, this RCC regimen addresses resistance to VEGF and mTOR inhibitors and improves progression-free survival.

A spray-dried powder combining leucine, sugar, and dual-size lactose improves inhalation stability, deliverability, and lung deposition.

A stable hydroxybenzamide intermediate and copper-catalyzed route cut toxicity and cost while delivering high-yield, high-purity piperazine.

Combining carboxyamidotriazole with mutation-targeted drugs improves lung cancer inhibition and helps address rapid resistance with low toxicity.

A CLDN6-targeted CAR with 4-1BB/CD3-zeta plus mRNA liposome vaccination boosts T-cell expansion, persistence, and solid tumor clearance.

Cyclodextrin linkers shield lipophilic payloads in protein conjugates to improve stability, bioavailability, and reduce off-target effects.

Topical ruxolitinib cream targets JAK1/JAK2 signaling to relieve atopic dermatitis itch while avoiding limits of steroids and systemic agents.

Dual-drug PLGA microspheres localize steroidal and NSAID release in joints for fast relief, months-long control, and fewer systemic side effects.